Skip to main content
Infilbray™ (venglustat) logo
A young woman who is sitting and painting, overlayed with purple light
A young woman who is sitting and painting, overlayed with purple light

Neurologic care—The gap in Gaucher disease type 3 management

What you’ll learn on this page:

  • Treating neurologic manifestations has historically been an unmet need in Gaucher disease type 31

Historically, therapies for Gaucher disease type 3 have not been able to cross the blood-brain barrier and remain active within the CNS2,3

Purple circles of varying sizes beside a vertical bar

While historical therapies can effectively treat Gaucher disease type 3 symptoms related to hepatomegaly, splenomegaly, thrombocytopenia, and anemia, they do not address any of the neurologic manifestations of Gaucher disease type 3.1,2,4

Patients with Gaucher disease type 3 may be vulnerable to progressive neurologic manifestations.2

Frequently asked questions

Definitions: CNS=central nervous system; GCS=glucosylceramide synthase; GL-1=glucosylceramide; lyso-GL-1=glucosylsphingosine.

Relevant pages to view:

Indication

INFILBRAY (venglustat) is indicated for the treatment of neurological manifestations of Type 3 Gaucher disease (GD3) in patients weighing at least 15 kg. 

Important Safety Information

Warnings and Precautions:
Suicidal Ideation and Behavior:

Suicidal ideation and behavior have been reported in patients with GD3 receiving INFILBRAY and in unapproved populations receiving another formulation of venglustat, both with and without a history of psychiatric disorders. Assess patients' underlying risk of psychiatric disorders prior to initiation and monitor for depressive symptoms or suicidal thoughts during treatment. Use caution when prescribing to patients with a history of psychiatric disorders. Inform patients or caregivers of the potential for behavioral and mood changes and to seek medical attention for manifestations of suicidal ideation and behavior, new onset or worsening depression, or other mood changes. Consider changing the therapeutic regimen, including possibly discontinuing INFILBRAY, if such events occur.

Lens Opacification in Pediatric Patients:

Lens opacification may occur in pediatric patients treated with INFILBRAY. In pediatric patients, perform ophthalmological assessment prior to initiation and annually during treatment. Advise pediatric patients and caregivers to report any visual disturbances during treatment.

Embryofetal Toxicity:

Based on animal studies, INFILBRAY may cause fetal harm when administered to a pregnant woman. Prior to initiation, verify pregnancy status in females of reproductive potential and advise them of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment and for 11 days after the last dose.

Adverse Reactions:
The most common adverse reactions reported in ≥10% of INFILBRAY-treated GD3 patients aged ≥12 years were diarrhea, splenomegaly, nausea, depression, gastroenteritis, and vomiting.


Drug Interactions:
Strong CYP3A Inhibitors: Avoid concomitant use with INFILBRAY. Strong CYP3A inhibitors increase venglustat exposure, which may increase the risk of adverse reactions. If concomitant use is unavoidable, reduce INFILBRAY dosage.

Strong or Moderate CYP3A Inducers: Avoid concomitant use with INFILBRAY. Strong or moderate CYP3A inducers decrease venglustat exposure, which may result in decreased efficacy. If concomitant use is unavoidable, monitor for reduced effectiveness.

Please see Full Prescribing Information for INFILBRAY.

Indication

Important Safety Information

References: 1. Zhong W et al. Acta Neurol Belg. 2024;124(4):1213-1223. 2. Schiffmann R et al. J Inherit Metab Dis. 2020;43(5):1056-1059. 3. Peterschmitt MJ et al. Clin Pharmacol Drug Dev. 2021;10(1):86-98. 4. Grabowski GA et al. The Online Metabolic and Molecular Bases of Inherited Disease. Accessed October 7, 2026. https://ommbid.mhmedical.com/content.aspx?bookid=2709&sectionid=225546056 5. Hughes DA et al. GeneReviews® [Internet]. Accessed October 7, 2026. https://www.ncbi.nlm.nih.gov/books/NBK1269/ 6. Donald A et al. Genet Med. 2025;27(9):101502. doi:10.1016/j.gim.2025.101502 7. Cerezyme (imiglucerase). Prescribing Information. Genzyme Corporation, Cambridge, MA. 8. Cerdelga (eliglustat). Prescribing Information. Sanofi. 9. Infilbray (venglustat). Prescribing Information. Genzyme Corporation, Cambridge, MA.

©2026 Sanofi. All rights reserved. All trademarks mentioned are the property of the Sanofi group. MAT-US-2608182-v1.0-11/2026. Last updated: November 2026.